pharmaceutical research

Azevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class, orally bioavailable vasopressin V1a receptor antagonists for neuropsychiatric disorders, neurodegeneration, neurodevelopment, and brain injury. Its lead candidate SRX246 has shown Phase 2 efficacy in pathological aggression in Huntington's disease and Intermittent Explosive Disorder. The company has four clinical and preclinical programs and has raised $56M in funding.

Read more

clinical stage drug development

BioSyntex Laboratories, LLC is a small, woman-owned drug discovery and design company developing nanotechnology-driven pharmaceuticals and hybrid therapeutics that combine biologically derived carriers such as vesicles, exosomes, and peptide ligands with small molecule payloads. Its platform targets neuroinflammation and infectious disease along the gut-brain axis, with delivery routes optimized for oral, intranasal, and vesicle-enabled CNS penetration. The company is advancing multiple drug candidates toward IND-enabling studies and welcomes collaborati

Read more

drug designdrug discoverynano-medicinetargeted drug delivery